Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.22%54.700.0%$1457.25m
GILDGilead Sciences, Inc. -0.70%72.671.0%$1278.46m
AMGNAmgen, Inc. 0.04%222.481.3%$637.69m
NVAXNovavax, Inc. 0.15%48.24102.0%$609.55m
REGNRegeneron Pharmaceuticals, Inc. -2.24%533.002.5%$603.18m
VRTXVertex Pharmaceuticals, Inc. -0.23%265.901.9%$515.16m
BIIBBiogen, Inc. 0.98%298.771.6%$417.07m
ILMNIllumina, Inc. 1.75%360.603.5%$360.95m
SRNESorrento Therapeutics, Inc. 1.52%5.351.8%$311.72m
SGENSeattle Genetics, Inc. 0.44%152.396.1%$244.10m
ALXNAlexion Pharmaceuticals, Inc. 0.00%102.802.0%$224.06m
AAgilent Technologies, Inc. 0.87%86.891.6%$197.86m
CODXCo-Diagnostics, Inc. -0.72%17.900.0%$184.59m
MGNXMacroGenics, Inc. -3.13%22.906.2%$172.69m
BMRNBioMarin Pharmaceutical, Inc. 6.39%103.744.3%$172.63m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.